Sikic Bi

642 total citations
13 papers, 547 citations indexed

About

Sikic Bi is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Sikic Bi has authored 13 papers receiving a total of 547 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 6 papers in Oncology and 3 papers in Organic Chemistry. Recurrent topics in Sikic Bi's work include Cancer therapeutics and mechanisms (7 papers), Drug Transport and Resistance Mechanisms (5 papers) and Chemokine receptors and signaling (2 papers). Sikic Bi is often cited by papers focused on Cancer therapeutics and mechanisms (7 papers), Drug Transport and Resistance Mechanisms (5 papers) and Chemokine receptors and signaling (2 papers). Sikic Bi collaborates with scholars based in United States. Sikic Bi's co-authors include RA Warnke, KG Blume, NJ Chao, Michiko Aihara, Guarino Am, Susan Arnold, Raymond L. Furner and Michael Koretz and has published in prestigious journals such as PubMed.

In The Last Decade

Sikic Bi

13 papers receiving 519 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sikic Bi United States 10 282 276 77 58 39 13 547
Yoshiaki Okuno Japan 20 248 0.9× 231 0.8× 57 0.7× 78 1.3× 45 1.2× 41 796
Hideyuki Tanimura Japan 12 347 1.2× 297 1.1× 100 1.3× 82 1.4× 34 0.9× 16 574
K Csóka Sweden 12 207 0.7× 246 0.9× 51 0.7× 47 0.8× 39 1.0× 19 503
Clifford Sachs United States 13 277 1.0× 359 1.3× 76 1.0× 22 0.4× 31 0.8× 20 720
JHM Schellens Netherlands 12 448 1.6× 412 1.5× 55 0.7× 72 1.2× 25 0.6× 16 626
Maria A.J. van Eijndhoven Netherlands 7 356 1.3× 258 0.9× 45 0.6× 73 1.3× 19 0.5× 8 520
Chris Benz United States 12 255 0.9× 231 0.8× 26 0.3× 86 1.5× 14 0.4× 27 539
H Fridborg Sweden 12 225 0.8× 239 0.9× 60 0.8× 30 0.5× 20 0.5× 20 480
T. L. Loo United States 10 175 0.6× 206 0.7× 42 0.5× 115 2.0× 26 0.7× 27 522
Stephan A. Veltkamp Netherlands 14 241 0.9× 245 0.9× 126 1.6× 61 1.1× 14 0.4× 19 640

Countries citing papers authored by Sikic Bi

Since Specialization
Citations

This map shows the geographic impact of Sikic Bi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sikic Bi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sikic Bi more than expected).

Fields of papers citing papers by Sikic Bi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sikic Bi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sikic Bi. The network helps show where Sikic Bi may publish in the future.

Co-authorship network of co-authors of Sikic Bi

This figure shows the co-authorship network connecting the top 25 collaborators of Sikic Bi. A scholar is included among the top collaborators of Sikic Bi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sikic Bi. Sikic Bi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Bi, Sikic. (1999). Modulation of multidrug resistance: a paradigm for translational clinical research.. PubMed. 13(5A). 183–7. 50 indexed citations
2.
Bi, Sikic, et al.. (1995). Drug resistance in clinical oncology and hematology. Introduction.. PubMed. 9(2). xi–xii. 18 indexed citations
3.
Warnke, RA, et al.. (1994). Mdr1 gene expression in childhood acute lymphoblastic leukemias and lymphomas: a critical evaluation by four techniques.. PubMed. 8(2). 327–35. 50 indexed citations
4.
Bi, Sikic, et al.. (1992). Use of etoposide in combination with cyclosporine for purging multidrug resistant leukemic cells from bone marrow in a mouse model.. PubMed. 377. 25–34. 1 indexed citations
5.
Chao, NJ, et al.. (1992). Purging multidrug resistant cells from bone marrow.. PubMed. 377. 13–23. 3 indexed citations
6.
Bi, Sikic, et al.. (1992). Use of etoposide in combination with cyclosporin for purging multidrug-resistant leukemic cells from bone marrow in a mouse model.. PubMed. 20(9). 1048–54. 10 indexed citations
7.
Aihara, Michiko, Sikic Bi, KG Blume, & NJ Chao. (1990). Assessment of purging with multidrug resistance (MDR) modulators and VP-16: results of long-term marrow culture.. PubMed. 18(8). 940–4. 12 indexed citations
8.
Bi, Sikic. (1986). Biochemical and cellular determinants of bleomycin cytotoxicity.. PubMed. 5(1). 81–91. 77 indexed citations
9.
Bi, Sikic, et al.. (1985). Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA.. PubMed. 45(9). 4091–6. 191 indexed citations
10.
Bi, Sikic, et al.. (1985). Bleomycin, mitomycin, and cisplatin therapy for advanced squamous carcinoma of the uterine cervix: a phase II study of the Northern California Oncology Group.. PubMed. 69(7-8). 903–5. 12 indexed citations
11.
Arnold, Susan, et al.. (1982). Adsorption of antineoplastic drugs following large-volume ip administration to rats.. PubMed. 66(1). 147–55. 25 indexed citations
12.
Bi, Sikic, et al.. (1981). Pulmonary disease as a complication of chlorozotocin chemotherapy.. PubMed. 65(3-4). 223–9. 9 indexed citations
13.
Bi, Sikic, et al.. (1978). Improved therapeutic index of bleomycin when administered by continuous infusion in mice.. PubMed. 62(12). 2011–7. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026